8-K: Tempest Therapeutics CFO Resigns, New CFO Appointed

Tempest Therapeutics announced the resignation of its Principal Financial and Accounting Officer, Justin Trojanowski, effective September 1, 2026, and the appointment of Nicholas Rossettos as his successor.

Summary

• Justin Trojanowski has resigned as Principal Financial Officer and Principal Accounting Officer of Tempest Therapeutics, Inc., with his departure effective September 1, 2026.
• Nicholas Rossettos has been appointed as the new Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary, also effective September 1, 2026.
• Mr. Rossettos brings over 30 years of financial executive experience, with a focus on biopharmaceutical and life sciences organizations.
• His prior roles include financial advisor to TransCode Therapeutics, Inc., Interim CFO of Sernova Corp., and consulting CFO services for emerging businesses.
• Mr. Rossettos is a CPA and holds degrees from Princeton University and Northeastern University.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it involves a routine executive transition without immediate positive or negative financial implications disclosed.

Positives

• Appointment of Nicholas Rossettos, a seasoned financial executive with over 30 years of experience, particularly in the biopharmaceutical sector.
• Rossettos has expertise in corporate finance, capital raising, financial reporting, and strategic transactions, which are valuable for a growth-stage company.
• The transition is planned with a clear effective date, allowing for a smooth handover.

Negatives

• Departure of the current Principal Financial and Accounting Officer, Justin Trojanowski, which can sometimes indicate underlying issues or a lack of confidence.

Risks

• Potential disruption during the transition period for financial reporting and strategic financial planning.
• The need for the new CFO to quickly integrate and understand the company's specific financial landscape and ongoing projects.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing regarding financial performance or strategic initiatives.

Management Comments

• No direct quotes from management regarding the transition were included in this filing.

Industry Context

StockSavvy.ai notes that executive turnover, particularly in finance roles, is not uncommon in the dynamic biotechnology sector, where companies often undergo significant financial and strategic shifts. The appointment of an experienced CFO is crucial for navigating capital markets and investor relations.

Comparison to Industry Standards

• The appointment of a CFO with over 30 years of experience, including specific biopharmaceutical expertise, aligns with industry best practices for companies in clinical development or seeking further funding.
• Companies like Sernova Corp. and TransCode Therapeutics, where the new CFO has held roles, are also in the clinical-stage biotechnology space, indicating a pattern of experience in similar environments.

Management Changes

Stakeholder Impact

• Shareholders: The transition of a key financial officer may lead to short-term uncertainty, but the appointment of an experienced executive is generally viewed positively for long-term financial stewardship.
• Employees: May experience a period of adjustment as the new CFO integrates into the company's operations and culture.
• Creditors/Suppliers: The company's financial reporting and management remain under the purview of experienced leadership, which should maintain confidence in financial obligations.

Next Steps

• Nicholas Rossettos will assume his new responsibilities as CFO, Treasurer, and Corporate Secretary.
• The company will manage the transition of financial officer duties from Justin Trojanowski to Nicholas Rossettos.

Key Dates

Keywords

CFO Appointment, Executive Transition, Financial Officer, Biopharmaceutical Finance, Corporate Governance, Financial Reporting, Capital Raising